Rapid Diagnostics for Antimicrobial Resistance in Cancer Patients
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 250
Special Issue Editor
Interests: nanoparticle-based biosensors; PCR-less genomic detection; genome-phenome approaches to antimicrobial resistance (AMR) detection; beta-lactam (carbapenem) resistance
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer patients are vulnerable to bacterial infection, which is a major cause of death. Infection of antimicrobial-resistant pathogens is an urgent threat to successful cancer treatment and recovery. Rapid diagnostics will be impactful in shortening the diagnosis of infection, leading to early treatment and early recovery.
This Special Issue welcomes papers related to the main topic, including but not limited to the etiology of infection to understand diagnosis, genomics, genome-phenome approaches to AMR, rapid diagnostics, surveillance, prevention, and prediction associated with antimicrobial resistance in oncology. Of interest are the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) and carbapenem-resistant Enterobacterales. Finally, we welcome papers that provide insights into ways to predict, prevent, and treat antibiotic-resistant infections that will positively impact the care and survival of cancer patients.
This Special Issue is in cooperation with the 2024 Global Alliance for Rapid Diagnostics Forum, organized by the Global Alliance for Rapid Diagnostics (GARD), Michigan State University, East Lansing, MI 48824.
Prof. Dr. Evangelyn C. Alocilja
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antimicrobial-resistant infection
- cancer patients
- carbapenem resistance
- pediatric cancer patients
- ESKAPE pathogens
- Enterobacterales
- rapid diagnostics
- biosensors
- prevention
